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Abstract
Fibroblasts like synoviocytes (FLS) play several significant roles in rheumatoid 
arthritis (RA) pathophysiology. This chapter will describe known roles of FLS in 
disease initiation, joint inflammation, disease persistence and joint destruction. 
It will describe the newly characterized subsets of FLS based on single cell RNA 
sequencing studies, and their association to specific aspects of the disease. Finally, 
we will discuss the future of targeting FLS in the treatment of RA. The FLS in the 
synovial lining layer are identified by surface complement decay-accelerating factor 
(CD55) along with lubricin and metallopeptidase expression. Pathological activa-
tion of this lining layer subset result in bone and cartilage damage in mice. FLS of 
the sublining layer are often characterized by THY1 expression, but recent studies 
have highlighted a heterogeneity where several distinct subsets are identified by 
additional markers. Sublining FLS expressing human leukocyte antigen-DRA 
(HLA-DRA) produce C-X-C motif chemokine 12 (CXCL12) and receptor activator 
of nuclear factor-κB ligand (RANKL) and seems to constitute a pro-inflammatory 
subset that is associated with inflammation and tertiary lymphoid structures. 
Another subset of FLS characterized by CD34 expression may discriminate a 
common progenitor fibroblast subset. Taken together, studies isolating and char-
acterizing gene expression in synovial FLS report both associations of unknown 
importance and markers that may impose protective or destructive features. This 
supports evidence of FLS as active players in RA pathology capable of cellular 
recruitment, local cellular crosstalk and promotion of joint destruction. These 
discoveries may serve as an atlas for synovial activation in RA and have identified 
several potential fibroblast markers for the development of targeted treatment.
Keywords: Fibroblast like synoviocytes, Rheumatoid arthritis, Inflammation, 
Autoimmunity, Tertiary lymphoid structures, Fibroblast activation protein, 
Fibroblast targeted treatment
1. Introduction
In normal resting conditions the synovial membrane is a thin layer of well-
ordered cells historically called type A and B synoviocytes. These cells form a 
barrier between the articular cavity and a sublining layer, the latter being heteroge-
neous and composed of several cell linages. Fibroblasts, immune cells and mature 
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vasculature (capillaries, arterioles and venules) made up of pericytes and endothe-
lia are some of the various cell types constituting this layer [1–3].
2. Rheumatoid arthritis
Rheumatoid arthritis (RA) has a multifactorial etiology and is one among the most 
common systemic autoimmune diseases [4, 5]. The factors that mediate the initiation of 
RA is yet to be unraveled. However, the pathology of RA involves abnormalities in both 
the innate and the adaptive immune system, and both of these systems are implicated 
with the progression and persistence of the disease [6, 7]. The synovial membrane is 
the primary site of pathology during the synovitis stage of the disease and character-
ized by proliferation of tissue resident, synovial cells and the infiltration of inflamma-
tory cells from the blood. RA is a chronic, progressive disease leading to degradation of 
articular cartilage and bone along with several systemic manifestations [8].
In RA, the inflamed synovial membrane undergoes hyperplasia and transforms into 
less structured lining layer and sublining tissues both rich in fibroblasts like synovio-
cytes (FLS) [9, 10]. This inflamed synovial membrane eventually begins to invade the 
cartilage surfaces and the underlying bone, commonly referred to as pannus [11, 12].
Present day treatment strategies for RA primarily focuses on suppression of 
cytokine signaling and T- and B-cell activity. These therapies have highlighted 
the importance of immune response in driving the progression of RA. However, 
they also clearly demonstrate that in a large proportion of patients these treat-
ments are incapable of inducing disease remission [8, 13]. Synovial phenotyping 
of RA patients based on histology has highlighted a fibroblast dominated synovial 
pathotype [14]. This pathotype is believed to include a large proportion of the non-
responders to conventional and biologic disease modifying anti-rheumatic drugs 
[15–17]. This is supported in vitro where anti-tumor necrosis factor alpha (TNFα) 
treatments were ineffective in cultures dominated by FLS [18]. Furthermore, a 
recently published, biopsy driven clinical trial in RA patients with inadequate 
response to anti-TNFα treatment, showed significantly higher response rates when 
patients with B-cell poor synovium were treated with IL-6 receptor inhibitor 
tocilizumab compared to the B-cell depleting agent rituximab [19].
In the following sections, we will first describe RA FLS in general before the era of 
single cell RNA sequencing (scRNA-seq). We will summarize the known and proposed 
roles of FLS in RA initiation, joint inflammation, disease persistence and joint destruc-
tion. Finally, we will describe the newly characterized subsets of FLS based on scRNA-
seq studies their connection to specific aspects of clinical disease, future outlooks in the 
context of RA diagnosis, RA tissue phenotyping and therapy targeting FLS.
3. Fibroblast like synovial cells in rheumatoid arthritis
3.1 Disease initiation
The central role of FLS in RA pathology is highlighted in murine studies dem-
onstrating that activation of FLS is sufficient to initiate local joint inflammation 
leading to persistent arthritis [20, 21].
Furthermore, FLS greatly contribute to the transformation of the thin synovial 
membrane into a multi-layered invasive hyperplastic pannus [22]. This expansion of 
FLS in the inflamed synovium is likely a result of at least one of the following processes. 
First, pathological subsets of FLS seem to proliferate to some extent and develop a local 
resistance to apoptosis [23–25]. Secondly, pluripotent mesenchymal stem cells may 
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migrate into the synovium from the circulation, where they differentiate into mature 
pathological subsets of FLS [26]. Lastly, a local mesenchymal progenitor cell popula-
tion may undergo activation and differentiation into distinct phenotypes of FLS [27]. 
Collectively, this leads to a local increase in pathological FLS in the RA synovium.
3.2 Joint inflammation
Pathogenic FLS constitute the majority of cells found in the inflamed synovial 
tissues, and play an important role in the inflammatory cascade, linking innate 
and adaptive immunity [6, 10]. FLS are capable of significantly affecting the local 
inflamed environment through production of cytokines and chemokines leading 
to recruitment and activation of immune cells [9, 28]. Specifically, pathogenic 
FLS are able to provide an adequate survival signal for synovial T-cells [29], a 
signal that is superior to the one produced by non-inflammatory fibroblasts [30]. 
This interaction between FLS and lymphocytes can inhibit the resolution of local 
inflammation [30, 31] through both paracrine and direct cell–cell interactions [32]. 
This pathogenic role of the FLS is facilitated by the up-regulation of several adhe-
sion molecules such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1) [6, 33]. In addition to recruitment and co-activation 
of T-cells in the inflamed joint, FLS have been shown to be able to present antigens 
on class II major histocompatibility complex (MHC-II) to CD4+ T-cells [34].
Furthermore, FLS are involved in the formation of tertiary lymphoid structures 
(TLS) in the RA synovium. Stromal cell populations such as the fibroblastic reticular 
cell support organization of these lymphocyte aggregates similarly to that of second-
ary lymphoid organs with distinct T- and B-cell niches [35]. Thymocyte differentiation 
antigen 1 (THY1, also known as CD90) and podoplanin (PDPN) positive fibroblast 
associated with TLS in RA (Table 1) produce several chemokines such as C-X-C motif 
ligand (CXCL) 13 and C-C motif ligand (CCL)21 implicated with lymphocyte recruit-
ment and organization [47, 48]. Another marker associated with the TLS associated 
fibroblast is the receptor activator of nuclear factor kappa-β ligand (RANKL), which is 
important in both bone homeostasis and lymph node development [35, 49].
Collectively, FLS may be involved in both the pro-inflammatory initiation in 
the synovium, lymphocyte recruitment and the organization of TLS. A fibroblast 
driven RA phenotype resulting in persistent inflammation and a lymphoid rich 
synovium similar to what have been shown by histology.
3.3 Disease persistence
The highly proliferating and pathogenic RA FLS are very different from their 
quiescent state during non-inflamed conditions where FLS control the structural 
integrity of the joint lining and sublining layer [22]. The immunological events 
initiating a pathogenic state of RA FLS is still not fully understood, but proliferation 
and transformation of the FLS may occur prior to immune infiltration [50].
In RA, subsets of FLS can differentiate to become inflammatory, migratory, 
and invasive, thus collectively fostering disease aggravation in various animal 
models of RA [45, 51, 52]. Constitutive activation is a hallmark of RA FLS and 
leads to production of several inflammatory cytokines, such as interleukin 
(IL)-1β, TNFα and IL-6 and chemokines such as monocyte chemoattractant 
protein 1 (MCP-1/CLL2) [9] and CXCL12 [53]. Even though the activation of RA 
FLS is greatly affected by pro-inflammatory factors in the local environment, 
epigenetic changes are also important [54]. Epigenetic changes lead to constitu-
tive activation even when the cells are removed from the inflamed environment 
and remain without addition of proinflammatory stimuli [52]. Moreover, a 
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recent study suggests a link between epigenetic-driven positional identity of 
FLS (e.g. small versus large joints and proximal versus distal joints) and clinical 
disease patterns [55]. This link is further supported by the finding of oncogenes 
at sites of tissue destruction [56, 57] together with a highly activated nuclear 
factor κ beta pathway in RA FLS [58].
Altered metabolic activity with increased glycolysis is another hallmark of RA 
FLS [59]. Metabolic reprogramming of FLS were recently connected to complement 
Classical synovial subsets in RA Markers
Fibroblast like synoviocytes [36–38] Vimentin, THY1, prolyl-5-hydroxylase, CDH11, CD45, HLA-DR, 
α-SMA, CD55
Macrophage like synoviocytes [36, 39–41] CD14, CD68, RFD7, CD163, CD206, HLA-DR, CD97
Tertiary lymphoid structure associated 
fibroblast [35]
PDPN, THY1, FAP, CXCL13, CCL21, RANKL, CD21
Fibrocyte [42] CD34, CD45, CD14, CD11, MHC-II
Single cell analysis of synovial fibroblast subsets in RA
Published studies and subsets Cluster markers Associated transcription profile
Stephenson et al. 2018 [43] Fibroblast sorting strategy:
CD45 - Propidium iodide - PDPN+
Sublining fibroblast THY1+
Lining fibroblast CD55+ HAS1
Mizoguchi et al. 2018 [44] Fibroblast sorting strategy:
CD45- CD31- CD235a- CD146- PDPN+






Sublining fibroblast CD34+ IL6, CXCL12, 
CCL2, OPG
Lining fibroblast THY1- CD34- CD55, PRG4, HAS1, MMP1, MMP3
Zhang et al. 2019 [10] Fibroblast sorting strategy:
CD45- CD31- PDPN+
SC-F1 (sublining) THY1+ CD34+ C3, FOS
SC-F2 (sublining) THY1+ 
HLA-DRAhigh
IL6, CXCL12
SC-F3 (sublining) THY1+ DKK3+ CADM1, COL8A2
SC-F4 (lining) THY1- CD55+ PRG4, HBEGF, CLIC5
Croft et al. 2019 [45] Reanalysis of human data from Zhang et al. [10].
F1 (sublining) THY1+ DKK3, OGN, CD9,
F2 (sublining) THY1+ MDK, COL8A1, AEBP1
F3 (sublining) THY1+ IRF1, EGR1, JUNB
F4 (lining) THY1- CLIC5, CD55, HBEGF
F5 (sublining) CD34+ C3, APOD
Single cell analysis of circulating mesenchymal cells in RA:
Published study and subset Associated transcription profile
Orange et al. 2020 [46] Fibroblast sorting strategy:
CD45- CD31- PDPN+
AC3 (sublining fibroblast phenotype) CD34, HLA-DR, DKK3, FAPα, CDH11
The table contains a list of surface and transcriptional profiles of fibroblast subsets, fibroblast like cell subsets and 
macrophage subsets (pre-scRNA-seq) related to rheumatoid arthritis. For scRNA-seq studies, fibroblast subset names 
refer to the original articles. “+” and “- “shows whether the cells of interest are positive or negative for the cellular 
markers. The cellular markers which are discussed in the text are also listed under abbreviations.
Table 1. 
Surface and transcriptional profiles of FLS subsets (and related cellular subsets) in rheumatoid arthritis.
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C3 and C3a receptor-activation. Here repeated inflammatory challenges resulted  
in a distinct pro-inflammatory phenotypic priming of FLS in mice models of  
arthritis [60].
On the opposite side, several factors attempt to facilitate remission of proinflam-
matory FLS. One such potential immune regulator is the MerTK expressing syno-
vial macrophage which in vitro reduce matrix metalloproteinase (MMP) production 
by lining layer FLS [61].
Thus, even though FLS are responsive to their inflammatory context they may 
possess a distinct positional identity which enables a cytokine-independent intrin-
sic activation contributing to disease persistence in RA.
3.4 Joint destruction
The severe joint destruction of late-stage RA is in part attributed to the pannus 
tissue which is rich in FLS. RA FLS are identified as invaders of the joint cartilage 
in vivo [62, 63], an invasive behavior that has been confirmed in vitro [64] and in 
mice [52]. FLS mediate cartilage degradation which is attributed to a combination 
of facilitating adhesion factors and production of proteases, here among several 
well-known matrix metalloproteinases (MMPs) [9, 52, 64]. Cartilage degradation 
is ameliorated when fibroblast activation protein (FAP) deficiency is induced in the 
human TNFα transgenic mice model of arthritis [65]. The invasiveness of patho-
logical RA FLS is further emphasized by human FLS migrating to other joints in 
mouse models of RA and degrading the implanted human cartilage [51]. Migration 
that may be facilitated by specific anticitrulinated protein antibodies [66]. Notably, 
the ex vivo invasiveness of FLS correlates with joint erosions [67].
Increased osteoclastic activity leading to bone erosions in RA is another major 
factor in joint destruction. Here FLS produce CXCL12, RANKL, dickkopf related 
protein (DKK) 1, etc. which may increase both osteoclast migration, differentia-
tion, proliferation/activation and inhibit osteoblast function [53, 68, 69].
4.  Single cell analysis of synovial fibroblast subsets in rheumatoid 
arthritis
4.1 Phenotyping of fibroblast like synovial cells
Increasing spatial and molecular resolution in present day cellular analysis are 
changing our view of the synovial membrane in RA. Most notable is the identification 
of different fibroblast subsets within the inflamed synovial membrane. Recent work 
and ongoing studies are utilizing scRNA-seq, CyTOF and flow cytometry cell sorting 
to further investigate and distinguish these subsets and their role in disease pathology.
Recent scRNA-seq studies have identified several distinct disease-associated 
subsets in the inflamed synovial membrane, often grouped as lining layer or sublin-
ing layer FLS [10, 43, 44], Figure 1. The present studies utilize flow cytometry 
assisted cell sorting and transcriptomic clustering strategies based on exclusion 
of hematopoietic lineage cells (CD45), endothelial cells (CD31), red blood cells 
(CD235a), and pericytes (CD146) while using PDPN or collagen production as a 
positive marker (Table 1).
4.2 Lining layer fibroblasts
A common finding in scRNA-seq studies confirms the presence of complement 
decay-accelerating factor (CD55) and absence of THY1 expression in FLS of the 
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lining layer (Table 1). Of note, Mizoguchi et al. [44] did not report histological data 
of CD55 distribution, but a high level of CD55 gene expression in CD34- THY1- 
lining layer fibroblasts. All scRNA-seq studies (Table 1) of joint tissue reported 
lubricin (PRG4) expression in the lining layer subset [10, 43–45]. All present stud-
ies showed similar patterns of gene expression pertaining to the potential markers 
of FLS presented in the following section.
Zhang et al. [10] and the reanalysis of the same human data by Croft et al. [45] 
both reported a distinct lining fibroblast subset, SC-F4 and F4 respectively. This 
lining fibroblast subset was associated with expression of chloride intracellular ion 
channel 5 (CLIC5) and heparin binding epidermal growth factor-like growth factor 
(HBEGF). Mizoguchi et al. [44] and Stephenson et al. [43] also reported increased 
hyaluronan synthase 1 (HAS1) and metallopeptidase expression.
HAS1 is important for hyaluronan production and is a response to pro-inflamma-
tory stimuli in RA synoviocytes. This activation results in hyaluronan cell coating, leu-
kocyte/monocyte recruitment and facilitation of fibroblast-monocytes binding [70].
CD55, a C3 convertase inhibitor, has received increasing interest in cancer, 
where CD55/CD97 binding is associated with several oncogenic properties such as 
invasion and migration [71]. In RA, CD55 positive FLS are exclusive to the lining 
layer and in proximity to CD97 positive macrophages, suggesting a possible mecha-
nism of crosstalk [36]. CD55 is not exclusive to RA [72], but it has been suggested as 
a protective factor in a mice model of immune complex mediated arthritis [73].
In the context of joint tissue, the mucin-like glycoprotein, PRG4, has been 
proposed as having a dual role comprising of well-known lubricating property and 
as a moderator of inflammation via NF-κβ pathways through interaction with both 
CD44 and toll-like receptors [74].
CLIC5 is present in several intracellular organelles, but predominantly located at 
the mitochondrial inner membrane, where it has been associated with modulation 
Figure 1. 
The figure is a schematic presentation of fibroblast subsets identified by scRNA-seq studies of synovial tissue 
from patients with rheumatoid arthritis. The subsets have been divided into lining layer FLS and sublining layer 
FLS. No scRNA-seq studies yet have examined fibroblast subsets from the synovial fluid. Based on grouping 
markers and transcription profiles listed in Table 1, we propose 4 sublining phenotypes. Cells have been divided 
by dashed lines when the cellular markers were not listed in all the original studies. THY-1 and PRG4 expression 
gradients from the lining layer to the sublining layer is shown by the color density of the red and blue bars. The 
cellular markers are discussed in the text and listed under abbreviations. TLS: Tertiary lymphoid structures.
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of reactive oxygen species [75]. However, no functional studies have been published 
regarding CLIC5 in RA.
The epidermal growth factor family member, HBEGF, is present and involved 
in several physiological processes such as wound healing, tumor formation and 
angiogenesis. One common topic is its association with cell migration, as seen in 
keratinocyte/fibroblast models and in enterocytes in necrotizing enterocolitis [76]. 
In RA, HBEGF positive macrophages have recently been shown to increase synovial 
fibroblast invasiveness in an in vitro model [77].
Several matrix metalloproteinases, MMP1, MMP3 and MMP14 was connected 
to a specific subset of FLS by Mizoguchi et al. [44]. These destructive enzymes have 
previously been connected to cartilage degradation in RA, but MMP14 was also 
noted by Mizoguchi et al. as a migratory factor [44].
Taken together, studies isolating and characterizing gene expression in lining 
layer fibroblasts report both associations of unknown importance and markers that 
may impose protective and destructive features. This suggests that the lining layer 
fibroblast subset is an active subset in RA pathology capable of cellular recruitment 
and significant local cellular crosstalk.
4.3 Sublining layer fibroblasts
The scRNA-seq studies have reported several distinct sublining subsets pre-
sented in Table 1. The initial study by Stephenson et al. [43] identified THY1 as a 
marker of sublining fibroblasts and the subsequent scRNA-seq studies confirmed 
THY1 as a specific, albeit not universal marker of sublining fibroblasts [10, 44, 45].
Zhang et al. characterized this heterogeneity of the sublining layer fibroblasts 
and defined three THY1+ groups with additional subset markers; CD34 defined 
the SC-F1 cluster, human leukocyte antigen (HLA)-DRAhigh defined the SC-F2 
cluster and DKK-3 defined the SC-F3 cluster. The SC-F2 in particular was signifi-
cantly increased in leukocyte-rich RA ssynovium compared to leukocyte-poor RA 
synovium and osteoarthritis (OA) synovium [10], suggesting these to encompass 
TLS-associated fibroblast subsets. Reanalysis of these human data by Croft et al. [45] 
enabled the distinction of four sublining layer fibroblast groups (F1–3,-5, Table 1).
As with the lining layer, large sets of multiomics data are available. Several 
markers connected to joint inflammation and destruction have been identified in 
these subsets. However, the markers most consistently reported are THY1, HLA-
DRA, CD34, DKK3.
THY1 is a glycoprotein present on the membrane of several different cells 
including endothelial and mesenchymal cells [78]. Among the functions associated 
with THY1 expression is cellular contact, CD97 binding, integrin binding,  
trans-endothelial migration and MMP-9 and CXCL8 secretion after binding to 
neutrophiles [78].
As with THY1, CD34 is an established marker in different cell types including 
several stromal cells, epi/endothelial cells and fibrocytes [79]. Its function is largely 
unknown but has been linked to proliferation, adhesion, differentiation and is 
proposed as a marker of progenitor subsets in both mesenchymal, epithelial and 
endothelial cells [79].
MHC molecule (both class I and II) functions are typically attributed to 
antigen presentation. Several MHC molecules have been associated with autoim-
mune disease. Examples are the association of the MHC-I molecule HLA-B27 
with ankylosing spondylitis, reactive arthritis and juvenile idiopathic arthritis 
subsets [80], and the association of MHC-II molecules HLA-DR1 and DR4 
association with RA [81]. The specific function of HLA-DRA in RA FLS is yet to 
be investigated.
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The DKK family of glycoproteins are well known modulators of WNT pathways 
connected to embryogenesis, bone formation and eye and skin development [82]. 
DKK-1 has been extensively described in fibroblasts from RA patients and is a key 
player in joint remodeling [69]. DKK-3 has been reported as a chondroprotective 
factor in OA [83] and suggested as a B-cell modulator whose absence aggravates 
autoimmune symptoms in a murine systemic lupus erythematosus model [84] and a 
CD8 T-cell modulator involved in antigen tolerance [85].
Enrichment of several genes related to pro-inflammatory cytokines and proteins 
related to bone metabolism in RA have been reported in sublining fibroblasts includ-
ing IL-6, MCP-1/CCL2, CXCL12 and RANKL. Two proteins not mentioned above is 
the RANKL decoy receptor osteoprotegerin (OPG) which inhibit osteoclastogenesis 
in synovial macrophages [86] and the relatively new osteoglycin (OGN) that may 
both be part of the vascular system and may affect osteoblast differentiation [87].
The interferon regulatory factor 1 (IRF1) is a significant component of the inter-
feron signature/inflammation pathway, through which TNF induces production of 
CXCL9–11 and in its absence diminishes B-cell activating factor expression [88].
The heparin-binding growth factor midkine (MDK) is less investigated than the 
above-mentioned cytokines but has been identified in human synoviocytes and asso-
ciated with leukocyte migration to the synovium and osteoclastogenesis in mice [89].
C3, a unifying step for all three complement activating pathways has previously 
been located around microvasculature in the sublining of the RA synovium [90].
The cellular adhesion molecule 1 (CADM1) is a transmembrane member of the 
immunoglobulin superfamily with no known relation to RA. It has been identified 
as a tumor suppressor gene in solid cancers such as squamous cell carcinoma a, but 
may contribute to infiltration in adult T-cell leukemia/lymphoma [91].
To summarize, the sublining layer is a heterogeneous compartment of the 
inflamed RA synovium, regarding both cell linages and especially fibroblast subsets 
(Table 1 and Figure 1). Several distinct fibroblast subsets have been identified, but 
recuring markers such as HLA-DRA, CD34 and DKK-3 are relatively unknown in 
the RA context. Results from scRNA-seq studies propose that the sublining layer 
fibroblast subsets are significantly involved in cellular crosstalk, leukocyte recruit-
ment, para- and autocrine pro-inflammatory stimulation, and joint tissue destruc-
tion. Notably, some distinguishing factors such as DKK-3 may be enriched to form 
a regulatory anti-inflammatory and pro self-tolerance subset with similar chon-
droprotective effects and immune modulation of antigen tolerance mentioned in 
the previous section. An HLA-DRAhigh/CXCL12/RANKLhigh associated subset may 
constitute the pro-inflammatory TLS associated fibroblast subsets and CD34 may 
discriminate a common progenitor fibroblast subset. Together, the presence of both 
pro-inflammatory subsets and potential anti-inflammatory and progenitor subsets 
suggests an ongoing cellular balancing throughout the sublining layer, which may 
open avenues for new research in treatment strategies targeting FLS.
4.4 Fibroblast like synoviocytes in rheumatoid arthritis compared to other 
arthritides
In RA, synovial division into lining/sublining layers suggests differentiated roles 
of subsets of FLS regarding cytokine production, joint destruction, and possible 
regulatory mechanisms.
The expansion of these distinct subsets is different in RA compared with OA. 
Mizoguchi et al. reported a greater fraction of the THY1+ CD34− (perivascular) 
subset but less of the THY1− CD34− (lining) subset in RA compared with OA [44]. 
Notably, here the proportion of THY1+ CD34− (perivascular) FLS correlated with 
leukocyte infiltration and ultrasonic and histological synovitis [44].
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Similarly, Zhang et al. reported an overabundance of the THY1+ CD34− HLA-
DRAhigh (SC-F2) subset with upregulated expression of CXCL12 and IL-6 and a 
THY1+ CD34+ (SC-F1) subset in RA. In contrast, lining FLS (SC-F4) were more 
fabundant in OA [10].
The causal link between distinct subsets and RA pathogenesis was investigated 
in mice by Croft et al. Here the mouse thy1− subset homologous to human lining 
FLS (F4) were correlated to joint damage and mouse thy1+ sublining FLS correlated 
to inflammation [45]. Notably, the elimination of FAP expressing subsets reduced 
pannus formation and joint destruction [45]. This suggests that FAP is a marker of 
pathologically active FLS in RA [45, 92, 93].
Comparison of subsets of FLS in RA and psoriatic arthritis are underway [94] 
and may potentially assist in discriminating these arthritides.
5. Fibroblasts derived from synovial fluid versus synovial tissue
Arthrocentesis is a common therapeutic procedure in treatment of RA. 
Fibroblast cultured from synovial fluid aspirates initially express similar phe-
notypical traits compared to tissue derived synovial fibroblast cultures [95, 96]. 
Despite these similarities, synovial fluid derived fibroblasts are likely a proxy 
regarding changes in the synovium and results must be interpreted as such. In 
both research and clinical settings synovial biopsies are both economical and well 
tolerated [97–100]. However, synovial fluid analysis of both cellular and soluble 
components is very useful in clinical settings where the length of consultations/
sterile procedural environments/analytic facilities may limit the use of synovial 
biopsies. To the authors knowledge, no studies have yet reported scRNA-seq 
analysis of synovial fluid fibroblasts.
6. Circulating mesenchymal fibroblast like cells in rheumatoid arthritis
In excess to tissue resident FLS, Orange et al. recently highlighted the pres-
ence of circulating fibroblast-like cells in the blood of RA patients shortly before 
symptomatic disease flare [46]. Interestingly these pre inflammatory mesenchymal 
(PRIME) cells show enrichment of previously reported markers of distinct sublin-
ing subsets of FLS e.g., DKK-3, CD34 and HLA-DR. This suggests that PRIME 
cells may constitute a heterogeneous pool of circulating FLS-like cells with distinct 
functions. Subsets of FLS migrating from the RA affected synovium, or a common 
homogeneous pool of circulating progenitor FLS awaiting recruitment signals from 
local sites of inflammation could potentially be the origin of these cells, although 
this remains to be investigated. Regardless, PRIME cells may not only be a useful 
marker predicting disease flares in RA, but also potentially explain how synovitis is 
transmitted from joint to joint [51].
7. Future therapeutic perspectives
The insights recently generated through high resolution scRNA-seq have revo-
lutionized our understanding of specific subsets of FLS in RA and their involve-
ment in driving different aspects of RA pathobiology. This understanding has also 
provided the basis for generating specific targetable markers of pathological subsets 
of FLS in RA. Targeting strategies that could be used as either monotherapy or as an 
add-on treatment to present day cytokine or lymphocyte inhibitors [101].
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FLS could be targeted by drugs used in fibrotic conditions such as nintedanib or 
pirfenidone [102]. However, these drugs are likely affecting a completely different 
aspect of fibroblast functions. Therefore, new drugs are needed. An example is the 
addition of the cyclin-dependent kinase inhibitor, Seliciclib, which is currently 
being evaluated [103].
The well-known FAP marker of activated stromal cells has a diagnostic and 
prognostic potential through precise and low background positron emission tomog-
raphy tracers developed in cancer-immunology [104]. The recent development 
of specific quinoline-based positron emission tomography tracers that act as FAP 
inhibitors have demonstrated promising results both preclinically and clinically in 
different cancers but could also be promising as diagnostic and prognostic markers 
of RA [105]. Further, the clinical potential of targeting FAP expressing FLS would 
be a targeted treatment eliminating pathologically activated RA FLS, in both the 
lining and the sublining layer [45, 93].
Among other interesting targets, NOTCH3 is one of the most recently in vivo 
validated pathological targets. NOTCH3 is expressed on the surface of RA FLS and 
linked with THY1 expression. NOTCH3 may also be a useful target in a therapeutic 
senescence strategy through selective activation of the g-protein coupled recep-
tor melanocontin type 1 receptor [106]. Furthermore, in an animal model of RA 
injection of NOTCH3-neutralizing monoclonal antibody attenuated the severity of 
arthritis. Taken together, the in vitro studies on NOTCH3, including its connection 
to spatial distribution of FLS and the above-mentioned animal study underline 
NOTCH3 as a promising therapeutical target in RA [106, 107]. Targeting the com-
plement C3 - C3a receptor axis may serve as another preventive or complementary 
strategy, where metabolic priming of FLS can be avoided or reduced [60]. Another 
possible strategy of targeting FLS is drug delivery via the extra domain A fibronec-
tin splice variant identified in OA and RA [108, 109] and utilized in cancer [110].
Several other reagents targeting FLS are currently being tested ranging from 
metabolite modulators to treatments targeting intracellular signal transduction or 
epigenetic changes [111].
Collectively, these therapies targeting subsets of FLS are emerging as promising 
diagnostic and therapeutic tools. Tools for optimized and stratified treatments in 
RA based on which cellular mechanisms and which fibroblast subsets are pathologi-
cally activated in the individual patient.
8. Conclusions
Collectively, pathological FLS presented in this chapter are deeply connected to 
the RA pathophysiology of disease initiation, joint inflammation, disease persis-
tence and joint tissue destruction.
Recent scRNA-seq studies have identified several distinct subsets of FLS causally 
linked to major elements of RA pathogenesis e.g., inflammation and joint destruc-
tion, while other subsets may present regulatory, pro-inflammatory TLS associated 
or common progenitor FLS.
These first steps in a scRNA-seq era of RA research warrants both rejoice and 
due diligence. Due diligence because we henceforth must appreciate the cellular 
diversity and the complex cellular crosstalk of the RA synovium. Like FLS, mono-
cytes/macrophages and lymphocytes exhibit distinct subsets in RA, which may 
be as important in understanding the spectrum of RA disease, e.g., lymphocyte 
dominated vs. lymphocyte poor synovium and erosive vs. non-erosive disease. 
Furthermore, we must appreciate the heterogeneity of FLS and cellular organiza-
tion (here among TLS formation) of the sublining layer.
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Rejoice because the recent subset studies have produced a language and knowl-
edge and a novel nomenclature for FLS in future research. A breakthrough that 
might enable clinicians in the future to modulate specific aspects of RA through 
fibroblast subset targeted treatment.
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